Severe ICP raises risk in twin pregnancy, study finds
Severe intrahepatic cholestasis of pregnancy (ICP) significantly raises the risks of adverse outcomes in twin pregnancies, according to a single-center, retrospective study conducted in…
News
Preclinical safety data support ETX-312 for MASH human trials
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
BARE holds Live and Let Live(r) fundraising campaign
Throughout July, the nonprofit Biliary Atresia Research & Education (BARE) is holding its Live and Let Live(r) fundraising campaign to raise money and awareness…
Antibody brings proteins together to tame autoimmune hepatitis
BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…
UDCA plus phenobarbital safe, effective for infant cholestasis
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…
Lanifibranor reduces abnormalities in liver blood vessel cells: Study
Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…
Hepatitis E virus can also infect kidney cells: Study
The hepatitis E virus (HEV) has long been known to infect liver cells, but researchers have now shown it is also able to infect…
Nearly half of PBC patients in US haven’t seen a specialist recently
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
Recurrent ICP linked to condition’s severity in 1st pregnancy
Nearly one in three patients diagnosed with intrahepatic cholestasis of pregnancy (ICP) during a first pregnancy will develop the condition again in a subsequent…
Pemvidutide shows benefit for MASH in Phase 2b clinical trial
Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…
